FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev as 1st-line treatment of metastatic colorectal cancer: results of the phase III randomized TRIBE trial.
ASCO Annual Meeting 2012
FOLFOXIRI/ bevacizumab ( bev ) versus FOLFIRI/ bev as first-line treatment in unresectable metastatic
